Insights & news

Van Bael & Bellis promotes Isabelle Van Damme

  • 01/02/2021
  • News

This week, Van Bael & Bellis promotes Isabelle Van Damme to its partnership. 

Isabelle specialises in international trade law (WTO and preferential trade agreements), EU law and public international law. She is a key member of Van Bael & Bellis’ exceptional International Trade and International Dispute Resolution teams.

Isabelle advises clients on WTO procedural and substantive law and represents governments in WTO dispute settlement proceedings. Her recent experience includes acting in the first WTO dispute in which the essential security exception clause in Article XXI of the GATT 1994 was interpreted and applied (DS512), and in the first significant challenge to the WTO compatibility of the EU’s climate policy measures (DS593).

Isabelle also advises governments and corporations on all aspects of the negotiation and implementation of preferential trade agreements and investment agreements. Her work on dispute settlement under preferential trade agreements includes designing a system of judicial remedies and advising a government in one of the first disputes arising under an EU preferential trade agreement.

Further, Isabelle has broad experience representing governments and individuals before various international courts and tribunals. She regularly advises and represents parties in cases before the World Trade Organization (WTO), the Court of Justice of the European Union (CJEU) and the European Court of Human Rights (ECtHR).

Notably, her blend of experience also means that she is uniquely placed to advise on the implications of Brexit. On Brexit-related matters, she has appeared as an expert witness before the Environment, Food and Rural Affairs Committee of the House of Commons and before the Northern Ireland Affairs Committee of the House of Commons. As a result, she will play a key role in the firm’s post-Brexit legal team, which recently won a place on the UK government’s post-Brexit Trade Law panel.

Managing partner, Philippe De Baere, comments: “Isabelle is an exceptional lawyer who has made a considerable contribution to Van Bael & Bellis’ international law practice. We are delighted to welcome her to the partnership and look forward to continued and new success as we expand our international presence and deepen our expertise even further in the areas of international dispute settlement and investment arbitration.”

Isabelle comments: “I am truly delighted to join the partnership of the firm and look forward to contributing to the continued growth of the firm’s International Dispute Resolution team, focusing on international trade and investment disputes, and helping our clients with all matters relating to Brexit, EU law and public international law. I also look forward to working with our excellent team of lawyers and staff in Brussels, Geneva and London to further strengthen the success of the firm.

Isabelle joined Van Bael & Bellis as an associate in 2016 and was promoted to Counsel in 2018. She previously worked as a référendaire in the chambers of Advocate General Sharpston at the Court of Justice of the European Union, and as an associate at an international law firm in Geneva.

Attachments:

Related insights

Sign up for updates
    • 19/03/2021
    • Articles

    Brexit - Medicinal Products - Commission Temporarily Redesigns Supply Chains to Cyprus, Ireland, Malta and Northern Ireland

    On 17 March 2021, the Official Journal of the European Union published Commission Delegated Regulation (EU) 2021/457 of 13 January 2021 “amending Delegated Regulation (EU) 2016/161 as regards a derogation from the obligation of wholesalers to decommission the unique identifier of products exported to the United Kingdom” (see, attached copy; the Delegated Regulation). The Delegated Regulation gives effect to a Commission Notice of 23 December 2020 in which the European Commission addressed the issues faced by market operators in Cyprus, Ireland, Malta and Northern Ireland, which are historically dependent on the United Kingdom for their medicine supplies, in complying with the EU’s pharmaceutical acquis following Brexit (see, Van Bael & Bellis Life Sciences News Alert of 23 December 2020). One of the issues identified was that there are currently no importers holding a manufacturing authorisation in Cyprus, Ireland, Malta and Northern Ireland. However, a manufacturing authorisation is required to affix a unique identifier on medicinal products which are imported from outside the EU and placed on the market in the EU. As there are currently no wholesalers in Cyprus, Ireland, Malta and Northern Ireland which can affix a unique identifier on medicinal products that are imported from the United Kingdom, the Delegated Regulation makes it possible for medicinal products which are exported from the EU to the United Kingdom to maintain their initial unique identifier. More precisely, the Delegated Regulation introduces a temporary derogation from the obligation of EU wholesalers to decommission the unique identifier of any medicinal products which they distribute in the United Kingdom. This will facilitate onward distribution of the medicines from the United Kingdom to the cited EU Member States and Northern Ireland. The exemption applies retroactively from 1 January 2021 and will apply until 31 December 2021. The unique identifier was introduced by the Falsified Medicines Directive (Directive 2011/62/EU) with a view to allowing wholesalers and healthcare professionals to verify the authenticity of medicinal products and to identify individual packs.

    Read more
    • 05/03/2021
    • News

    Cross-Border Litigation in the Post-Brexit World: A View from London and Brussels

    Following the UK’s exit from the EU on 31 January 2020 and the end of the transition period under the Withdrawal Agreement, unless proceedings were issued on or before 31 December 2020, the Brussels Recast Regulation no longer applies to questions of jurisdiction and the enforcement of court judgments between the UK and EU Member States. Nothing in the EU-UK Trade and Co-operation Agreement (EU-UK TCA) changes this position. Since the UK has not yet acceded to the 2007 Lugano Convention, issues relating to jurisdiction and the enforcement of judgments as between the UK and EU Member States will be governed by the 2005 Hague Convention on Choice of Court Agreements or, where not applicable, by domestic law (including any relevant bilateral conventions which have been incorporated into domestic law). This Client Alert provides an overview of the new rules applicable to post Brexit cross-border litigation with a particular focus on the impact of such changes in England and in Belgium. It also raises some practical considerations for clients to consider in thinking about cross-border litigation involving the UK and EU Member States. For the benefit of certainty, arbitration may be an attractive option for clients concerned about potential cross-border litigation as between UK and EU parties.

    Read more
    • 04/02/2021
    • Articles

    Brexit Implications for Data Protection in 8 Questions | Q&A Update under Brexit Trade Deal

    On 24 December 2020, the UK and the EU agreed a Trade and Cooperation Agreement regulating relations between both parties after Brexit. The TCA covers several topics, including data protection. Meanwhile, Brexit continues to raise many legal questions and uncertainties, not least as regards protecting personal data that flows between the UK and the rest of Europe. Do organisations in the UK still have to comply with the General Data Protection Regulation (GDPR)? Can they still transfer personal data to the European Economic Area (EEA)? Do they need to appoint a representative in the EU? And what happens with the “one-stop-shop”? Based on eight frequently asked questions, we provide an overview of issues to consider and steps to take to be compliant with data protection rules in the EEA and the UK. Please read our updated Q&A on the topic.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *